Natera Stock Jumps As NCCN Endorses Signatera MRD Test

Natera Inc. stocks have been trading up by 12.39 percent amid strong optimism over its latest clinical test advancements.

Live Update At 14:33:04 EDT: On Wednesday, June 24, 2026 Natera Inc. stock [NASDAQ: NTRA] is trending up by 12.39%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Natera (NTRA) has been trading like a momentum name with real fundamentals behind it. On 2026/06/24, NTRA ripped from a $243 open to close near the highs at $263.84, a powerful trend day that broke above the prior week’s range. Looking back to 2026/06/11, the stock has climbed from a close around $219 to the mid‑$260s, a roughly 20% move in less than two weeks. That is the kind of volatility active traders look for.

Intraday on 2026/06/24, NTRA showed steady accumulation. After a morning push from the $240s into the $250s, the stock based between $253 and $261 for hours, then squeezed into the close, finishing near session highs. That late‑day strength often signals real demand, not just a one‑and‑done headline pop.

Fundamentally, Natera is still a high‑growth, loss‑making story. Revenue over the last year was about $2.31B, growing more than 40% annually, with a strong 65.1% gross margin. But profitability ratios are deeply negative: EBIT margin at about ‑13% and return on equity around ‑37%. The balance sheet, however, is solid for a high‑growth diagnostics play, with a current ratio near 3 and modest total debt to equity of 0.13.

More Breaking News

• NXTS Stock Sparks Volatility As Traders Zero In On Cash Runway
• AFRM Extends CPP Deal As Price Target And Charter Hopes Lift Momentum
• BTQ Technologies Stock Draws Traders On Quantum-Security Hype
• MRNA Stock Jumps As Flu Win And Expansion Fuel Momentum

For traders, that mix — fast growth, improving cash flow, and manageable leverage — supports the aggressive multiples NTRA commands, while also keeping the chart highly sensitive to fresh catalysts.

Why Traders Are Watching NTRA Now

Natera is front and center this week because its flagship Signatera minimal residual disease (MRD) test just scored a huge validation. The National Comprehensive Cancer Network updated its bladder cancer guidelines to embed ctDNA‑MRD testing and effectively gave Signatera a Category 1 recommendation, the highest level, for guiding adjuvant immunotherapy decisions in muscle‑invasive bladder cancer after surgery. In plain English, top cancer experts just told the oncology world that Signatera belongs in the standard playbook.

For NTRA traders, that is not a soft, feel‑good headline. Category 1 status, paired with Signatera’s recent FDA companion diagnostic approval, means oncologists now have guideline‑backed and regulator‑blessed support to use this specific test to decide who gets costly immunotherapy. That tends to drive real test volume, and over time, recurring revenue.

Wall Street is lining up behind that thesis. RBC Capital Markets resumed coverage on Natera with an Outperform rating and a $275 target, pointing to the company’s greater than 90% share in oncology MRD testing and more than 70% year‑over‑year Signatera growth to over $1B in annualized revenue. BTIG pushed its Natera target from $250 to $270, explicitly tying the bump to Signatera’s NCCN win and the expectation of higher oncologist adoption. Leerink also reiterated an Outperform and flagged the bladder guideline update — which uniquely names Signatera — as a meaningful catalyst for community oncology uptake.

The irony is that on 2026/06/23, when the NCCN Category 1 news hit, NTRA traded down more than 2% premarket. That kind of “down on great news” action usually tells you the stock was crowded, with traders taking profits after a big run. But the sharp rebound into 2026/06/24’s breakout shows dip buyers were ready and watching the same structural story.

On top of oncology, Natera is working to turn its Prospera transplant test into a second growth engine. The company will present 21 studies — seven of them oral presentations — at the American Transplant Congress. Data show Prospera’s donor‑derived cell‑free DNA can flag trouble even when biopsies are negative, and that persistently low levels line up with much lower rejection and graft loss. For NTRA traders, that is another validation loop that supports a broader diagnostics platform, not just a single‑product story.

Conclusion

Natera sits at a classic high‑conviction but high‑expectation stage that active traders know well. On the one side, you have powerful fundamentals: NCCN Category 1 backing for Signatera in muscle‑invasive bladder cancer, recent FDA companion diagnostic approval, and multiple bullish notes from RBC, BTIG, and Leerink all pointing to durable leadership in MRD testing. NTRA’s >90% MRD share and >70% Signatera growth to more than $1B annualized revenue show this is not a concept; it is already a scaled business.

On the other side, the valuation is rich. NTRA trades around 11.8x sales and over 180x cash flow, with negative EPS and double‑digit negative returns on equity and assets. That is why price can whip around on news — expectations are baked in, and any surprise brings fast reactions. The premarket dip after the NCCN headline is a reminder that even the best stories can see sharp pullbacks as traders lock in gains. As millionaire penny stock trader and teacher Tim Sykes, says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” In a name like Natera, that trading mindset matters, because volatility and sharp reversals are part of the process, not an anomaly.

The broader picture, though, is a company turning big clinical wins into chart momentum. Strong cash, a manageable leverage profile, and expanding validation for both Signatera and Prospera give Natera real ammunition for the next phase of growth.

For NTRA watchers, the blueprint is the same one Tim Sykes pounds into students: “React to the market, don’t predict it. Let the chart and the catalysts prove themselves, and always, always cut losses quickly.” This article is for educational and research purposes only, but that mindset fits Natera perfectly right now — respect the trend, know the risks, and let the price action confirm the story.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks